Citations (106)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Rimei Nishimura, Tomomi Takeshima, Kosuke Iwasaki & Sumiko Aoi. (2023) Prescription patterns and therapeutic effects of second-line drugs in Japanese patients with type 2 diabetes mellitus: Analysis of claims data for metformin and dipeptidyl peptidase-4 inhibitors as the first-line hypoglycemic agents. Expert Opinion on Pharmacotherapy 24:8, pages 969-976.
Read now
Read now
Mitsuyoshi Takahara, Toshihiko Shiraiwa, Taka-aki Matsuoka, Kaoru Yamamoto, Yoshifumi Maeno, Yuka Shiraiwa, Yoko Yoshida, Naoto Katakami, Hiroaki Iijima, Hideyuki Katsumata, Kenji Arakawa, Toshio Hashimoto & Iichiro Shimomura. (2020) Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes. Diabetes, Metabolic Syndrome and Obesity 13, pages 4457-4468.
Read now
Read now
Masahiro Takihata & Yasuo Terauchi. (2019) The efficacy and safety of luseogliflozin and sitagliptin depending on the sequence of administration in patients with type 2 diabetes mellitus: a randomized controlled pilot study. Expert Opinion on Pharmacotherapy 20:17, pages 2185-2194.
Read now
Read now
Nobuya Inagaki, Shin-ichi Harashima & Hiroaki Iijima. (2018) Canagliflozin for the treatment of type 2 diabetes: a comparison between Japanese and non-Japanese patients. Expert Opinion on Pharmacotherapy 19:8, pages 895-908.
Read now
Read now
Takahiro Takase, Akinobu Nakamura, Chiho Yamamoto, Tatsuya Atsumi & Hideaki Miyoshi. (2018) Improvement in the proinsulin/C-peptide ratio during treatment with ipragliflozin in Japanese patients with type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 19:7, pages 631-632.
Read now
Read now
Maki Goda, Tomoko Yamakura, Kazuyo Sasaki, Takumi Tajima & Makoto Ueno. (2018) Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan. Current Medical Research and Opinion 34:2, pages 319-327.
Read now
Read now
Joseph A Messana, Stanley S Schwartz & Raymond R Townsend. (2017) An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes. Vascular Health and Risk Management 13, pages 43-54.
Read now
Read now
Konstantinos P. Imprialos, Konstantinos Stavropoulos, Michael Doumas, Asterios Karagiannis & Vasilios G. Athyros. (2017) The effect of SGLT2 inhibitors on cardiovascular events and renal function. Expert Review of Clinical Pharmacology 10:11, pages 1251-1261.
Read now
Read now
Yaowen Wang, Xueting Hu, Xueying Liu & Zengqi Wang. (2016) An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients. Therapeutics and Clinical Risk Management 12, pages 1113-1131.
Read now
Read now
Hiroyuki Ito, Masahiro Shinozaki, Shinya Nishio & Mariko Abe. (2016) SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan. Expert Opinion on Pharmacotherapy 17:15, pages 2073-2084.
Read now
Read now
Hiroshi Maegawa, Kazuyuki Tobe, Hiromi Tabuchi & Ichiro Nakamura. (2016) Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice. Expert Opinion on Pharmacotherapy 17:15, pages 1985-1994.
Read now
Read now
Stanley S. Schwartz & Intekhab Ahmed. (2016) Sodium–glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes. Current Medical Research and Opinion 32:5, pages 907-919.
Read now
Read now
Tamer Yacoub. (2016) Dapagliflozin combination therapy in type 2 diabetes mellitus. Postgraduate Medicine 128:1, pages 124-136.
Read now
Read now
Nobuya Inagaki, Maki Goda, Shoko Yokota, Nobuko Maruyama & Hiroaki Iijima. (2015) Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus: post hoc subgroup analyses according to body mass index in a 52-week open-label study. Expert Opinion on Pharmacotherapy 16:11, pages 1577-1591.
Read now
Read now
Articles from other publishers (92)
İsmail Ünal, Derya Cansız, Merih Beler, Zehra Sezer, Elif Güzel & Ebru Emekli-Alturfan. (2023) Sodium-dependent glucose co-transporter-2 inhibitor empagliflozin exerts neuroprotective effects in rotenone-induced Parkinson’s disease model in zebrafish; mechanism involving ketogenesis and autophagy. Brain Research 1820, pages 148536.
Crossref
Crossref
Michail Koutentakis, Jakub Kuciński, Damian Świeczkowski, Stanisław Surma, Krzysztof J. Filipiak & Aleksandra Gąsecka. (2023) The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?. Journal of Cardiovascular Development and Disease 10:11, pages 465.
Crossref
Crossref
Lu Chen, Qingxia Xue, Chunyan Yan, Bingying Tang, Lu Wang, Bei Zhang & Quan Zhao. (2023) Comparative safety of different recommended doses of sodium–glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials. Frontiers in Endocrinology 14.
Crossref
Crossref
Junichi Mukai, Nakaba Okamura, Yuki Saito & Rie Kubota. (2023) A systematic review of sodium-glucose cotransporter 2 inhibitors and renal profiles among Japanese patients with type 2 diabetes mellitus. Journal of Pharmaceutical Health Care and Sciences 9:1.
Crossref
Crossref
Ema Schönberger, Vjera Mihaljević, Kristina Steiner, Sandra Šarić, Tomislav Kurevija, Ljiljana Trtica Majnarić, Ines Bilić Ćurčić & Silvija Canecki-Varžić. (2023) Immunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging. International Journal of Environmental Research and Public Health 20:17, pages 6671.
Crossref
Crossref
Chun Xing Li, Li Yan Liu, Chen Xiao Zhang, Xu Hua Geng, Si Meng Gu, Yu Qiao Wang, Hua Liu, Qing Xie & Shuo Liang. (2023) Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials. Frontiers in Endocrinology 14.
Crossref
Crossref
Shuyan Gu, Xiaoqian Hu, Lizheng Shi, Xuemei Zhen, Xueshan Sun, Minzhuo Huang, Yuxuan Gu & Hengjin Dong. (2022) Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine 11:23, pages 7094.
Crossref
Crossref
Xi Rong, Yawen Zhu, Bo Wen, Kai Liu, Xinran Li, Qiling Gou & Xiaoping Chen. (2022) Risk of hypovolemia associated with sodium–glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Yudai Uehira, Hiroaki Ueno, Emi Ebihara, Taisuke Uchida, Hiroki Nabekura, Hideyuki Sakoda, Tadato Yonekawa, Hideki Yamaguchi & Masamitsu Nakazato. (2022) Current status of diabetes treatment in Miyazaki Prefecture, Japan: Results of a questionnaire survey conducted in 2016 and 2020. Journal of Diabetes Investigation 13:6, pages 1011-1020.
Crossref
Crossref
Bin Zhou, Yetan Shi, Rongrong Fu, Haixiang Ni, Lihu Gu, Yuexiu Si, Mengting Zhang, Ke Jiang, Jingyi Shen, Xiangyuan Li & Xing Sun. (2022) Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology 13.
Crossref
Crossref
Akinobu Nakamura. (2022) Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Pancreatic β-Cell Mass and Function. International Journal of Molecular Sciences 23:9, pages 5104.
Crossref
Crossref
Qiang Geng, Fangjie Hou, Yonghuan Zhang, Zhengzhong Wang & Meiling Zhao. (2022) Effects of different doses of canagliflozin on blood pressure and lipids in patients with type 2 diabetes: a meta-analysis. Journal of Hypertension 40:5, pages 996-1001.
Crossref
Crossref
Shi-di Zhao, Ling Zhou, Yi-ying Tao, Yue Yue, Jia-xin Wang, Lei Shen, Guo-yuan Lu & Yong-fu Hang. (2021) Renal outcomes in Asian patients with type 2 diabetes mellitus treated with SGLT2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. International Journal of Diabetes in Developing Countries 42:2, pages 178-190.
Crossref
Crossref
Dong-Dong Wang, Yi-Zhen Mao, Yang Yang, Tian-Yun Wang, Ping Zhu, Su-Mei He & Xiao Chen. (2022) Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Weight in Type 2 Diabetes Mellitus and Therapeutic Regimen Recommendation. Journal of Diabetes Research 2022, pages 1-13.
Crossref
Crossref
Nobuya Inagaki, Masaomi Nangaku, Yasushi Sakata, Kazuyo Sasaki, Kazumi Mori-Anai, Tomohisa Iwasaki & Koume Hamada. (2021) Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance. Advances in Therapy 39:1, pages 674-691.
Crossref
Crossref
Rimei Nishimura, Mayumi Taniguchi, Tomomi Takeshima & Kosuke Iwasaki. (2021) Efficacy and Safety of Metformin Versus the Other Oral Antidiabetic Drugs in Japanese Type 2 Diabetes Patients: A Network Meta-analysis. Advances in Therapy 39:1, pages 632-654.
Crossref
Crossref
Li Fang, Jiayu Duan, Jinsong Geng, Zhangsuo Liu & Jiancheng Dong. (2021) Sodium-glucose cotransporter 2 (SGLT2) inhibitors for the prevention and treatment of diabetic kidney disease: A network meta-analysis of randomized controlled trials. Diabetic Nephropathy 1:3, pages 114-124.
Crossref
Crossref
Tobias Täger, Dan Atar, Stefan Agewall, Hugo A. Katus, Morten Grundtvig, John G. F. Cleland, Andrew L. Clark, Hanna Fröhlich & Lutz Frankenstein. (2020) Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Heart Failure Reviews 26:6, pages 1421-1435.
Crossref
Crossref
Cheol Son, Hisashi Makino, Masato Kasahara, Tomohiro Tanaka, Kunihiro Nishimura, S. Taneda, Takeshi Nishimura, Shu Kasama, Yoshihiro Ogawa, Yoshihiro Miyamoto & Kiminori Hosoda. (2021) Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium–glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus: Results from the CANTABILE study. Diabetes Research and Clinical Practice 180, pages 109037.
Crossref
Crossref
Tomoya Ueda, Shu Kasama, Masahiro Yamamoto, Tomoya Nakano, Kazuhiro Ueshima, Yoshinobu Morikawa, Hiroyuki Kawata, Akiomi Yoshihisa, Masafumi Nakayama, Sei Komatsu, Tsunenari Soeda, Makoto Watanabe, Rika Kawakami, Yasushi Okada, Hiroyuki Tanaka, Yutaka Susuta, Masato Kasahara, Kenichi Tsujita, Yasuchika Takeishi & Yoshihiko Saito. (2021) Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes. Circulation Reports 3:8, pages 440-448.
Crossref
Crossref
Junichi Mukai, Shinya Kanno & Rie Kubota. (2021) A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus. Scientific Reports 11:1.
Crossref
Crossref
Nanjing Shi, Yetan Shi, Jingsi Xu, Yuexiu Si, Tong Yang, Mengting Zhang, Derry Minyao Ng, Xiangyuan Li & Fei Xie. (2021) SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Public Health 9.
Crossref
Crossref
Yasuhiro Watanabe, Daisuke Suzuki, Nobuichi Kuribayashi, Daigaku Uchida, Mitsutoshi Kato, Hiroshi Ohashi, Daiji Nagayama, Takashi Yamaguchi, Masahiro Ohira, Atsuhito Saiki & Ichiro Tatsuno. (2021) A randomized controlled trial of two diets enriched with protein or fat in patients with type 2 diabetes treated with dapagliflozin. Scientific Reports 11:1.
Crossref
Crossref
Vivencio Barrios & Carlos Escobar. (2021) Canagliflozin: metabolic, cardiovascular and renal protection. Future Cardiology 17:3, pages 443-458.
Crossref
Crossref
Junichi Mukai, Ayano Yoshiyama & Rie Kubota. (2020) Clinical relevance between sodium-glucose co-transporter 2 inhibitors and lipid profiles in Asian patients with type 2 diabetes mellitus: a systematic review with a meta-analysis of randomized controlled trials. Journal of Pharmaceutical Health Care and Sciences 6:1.
Crossref
Crossref
Chu Lin, Xiaoling Cai, Wenjia Yang, Fang Lv, Lin Nie & Linong Ji. (2020) Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. BMC Medicine 18:1.
Crossref
Crossref
Fan Yang, Ran Meng & Da‐Long Zhu. (2020) Cardiovascular effects and mechanisms of sodium‐glucose cotransporter‐2 inhibitors. Chronic Diseases and Translational Medicine 6:4, pages 239-245.
Crossref
Crossref
Charalampos Loutradis, Eirini Papadopoulou, Elena Angeloudi, Asterios Karagiannis & Pantelis Sarafidis. (2020) The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia. Current Medicinal Chemistry 27:39, pages 6682-6702.
Crossref
Crossref
Adriana Sánchez-García, Mario Simental-Mendía, Juan Manuel Millán-Alanís & Luis E. Simental-Mendía. (2020) Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials. Pharmacological Research 160, pages 105068.
Crossref
Crossref
Xi Rong, Xinran Li, Qiling Gou, Kai Liu & Xiaoping Chen. (2020) Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials. Diabetes and Vascular Disease Research 17:5, pages 147916412095362.
Crossref
Crossref
Sushrima GanAdem Y. Dawed, Louise A. DonnellyAnand T.N. NairColin N.A. PalmerViswanathan Mohan & Ewan R. Pearson. (2020) Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 43:8, pages 1948-1957.
Crossref
Crossref
Kazuomi Kario, Keith C. Ferdinand & James H. O'Keefe. (2020) Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. Progress in Cardiovascular Diseases 63:3, pages 249-262.
Crossref
Crossref
Mengdie Hu, Xiaoling Cai, Wenjia Yang, Simin Zhang, Lin Nie & Linong Ji. (2020) Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon‐Like Peptide‐1 Receptor Agonist and Sodium‐Glucose Cotransporter‐2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta‐Analysis. Journal of the American Heart Association 9:7.
Crossref
Crossref
Huilin Tang, Keming Yang, Xin Li, Yiqing Song & Jiali Han. (2020) Pancreatic safety of sodium‐glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis. Pharmacoepidemiology and Drug Safety 29:2, pages 161-172.
Crossref
Crossref
Wayne Huey-Herng Sheu, Siew Pheng ChanBien J. MatawaranChaicharn DeerochanawongAmbrish MithalJuliana ChanKetut SuastikaChin Meng KhooHuu Man NguyenJi LinongAndrea LukKun-Ho Yoon. (2020) Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations. Diabetes & Metabolism Journal 44:1, pages 11.
Crossref
Crossref
Sanaz Kamalinia, Robert G. Josse, Patrick J. Donio, Lindsay Leduc, Baiju R. Shah & Sheldon W. Tobe. (2019) Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis. Endocrinology, Diabetes & Metabolism 3:1.
Crossref
Crossref
Chaicharn Deerochanawong, Siew P. Chan, Bien J. Matawaran, Wayne H.‐H. Sheu, Juliana Chan, Nguyen H. Man, Ketut Suastika, Chin M. Khoo, Kun‐Ho Yoon, Andrea Luk, Ambrish Mithal & Ji Linong. (2019) Use of sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations. Diabetes, Obesity and Metabolism 21:11, pages 2354-2367.
Crossref
Crossref
Ban Liu, Yuliang Wang, Yangyang Zhang & Biao Yan. (2019) Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction. Current Topics in Medicinal Chemistry 19:20, pages 1818-1849.
Crossref
Crossref
Konstantinos Imprialos, Konstantinos Stavropoulos & Vasilios Papademetriou. (2019) Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure. Heart Failure Clinics 15:4, pages 519-530.
Crossref
Crossref
Lidan Yang, Lin Zhang, He He, Mei Zhang & Zhenmei An. (2019) Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in East Asians with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Therapy 10:5, pages 1921-1934.
Crossref
Crossref
Shu Kasama, Tohru Masuyama, Shiro Uemura, Yukihito Sato, Shinya Hiramitsu, Izuru Masuda, Kazuhiro Yamamoto, Sei Komatsu, Toshihisa Anzai, Kunihiro Nishimura, Tomoya Ueda, Masato Kasahara, Hiroyuki Tanaka, Yutaka Susuta & Yoshihiko Saito. (2019) Rationale and Design of the CANONICAL Study ― Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Canagliflozin for Heart Failure With Preserved Ejection Fraction With Type 2 Diabetes Mellitus ―. Circulation Reports 1:8, pages 347-351.
Crossref
Crossref
Charalampos Loutradis, Eirini Papadopoulou, Marietta Theodorakopoulou, Asterios Karagiannis & Pantelis Sarafidis. (2019) The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection. Future Medicinal Chemistry 11:11, pages 1285-1303.
Crossref
Crossref
Tomonari Kimura, Kazufumi Nakamura, Toru Miyoshi, Masashi Yoshida, Kaoru Akazawa, Yukihiro Saito, Satoshi Akagi, Yuko Ohno, Megumi Kondo, Daiji Miura, Jun Wada & Hiroshi Ito. (2019) Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet. International Heart Journal 60:3, pages 728-735.
Crossref
Crossref
Tadashi Toyama, Brendon L. Neuen, Min Jun, Toshiaki Ohkuma, Bruce Neal, Meg J. Jardine, Hiddo L. Heerspink, Muh Geot Wong, Toshiharu Ninomiya, Takashi Wada & Vlado Perkovic. (2019) Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 21:5, pages 1237-1250.
Crossref
Crossref
Chen Wang, Yue Zhou, Zili Kong, Xiang Wang, Wenshan Lv, Zhuang Geng & Yangang Wang. (2019) The renoprotective effects of sodium‐glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 21:4, pages 1018-1026.
Crossref
Crossref
Yuichiro Ito, James Van Schyndle, Takuya Nishimura, Toshifumi Sugitani & Tomomi Kimura. (2019) Characteristics of Patients with Diabetes Initiating Sodium Glucose Co-transporter-2 Inhibitors (SGLT2i): Real-World Results from Three Administrative Databases in Japan. Diabetes Therapy 10:2, pages 549-562.
Crossref
Crossref
Ann M. McNeill, Glenn Davies, Eliza Kruger, Stacey Kowal, Tim Reason, Flavia Ejzykowicz, Hakima Hannachi, Nilo Cater & Euan McLeod. (2019) Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis. Diabetes Therapy 10:2, pages 473-491.
Crossref
Crossref
Awadhesh Kumar Singh, Ambika G. Unnikrishnan, Abdul H. Zargar, Ajay Kumar, Ashok K. Das, Banshi Saboo, Binayak Sinha, Kalyan Kumar Gangopadhyay, Pradeep G. Talwalkar, Samit Ghosal, Sanjay Kalra, Shashank Joshi, Surendra Kumar Sharma, Usha Sriram & Viswanathan Mohan. (2019) Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians. Diabetes Therapy 10:2, pages 393-428.
Crossref
Crossref
Chaojie Feng, Minxiang Wu, Zhengyue Chen, Xiongwei Yu, Zhenyu Nie, Yu Zhao & Beiyan Bao. (2019) Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. International Urology and Nephrology 51:4, pages 655-669.
Crossref
Crossref
Izabela Rodrigues Figueiredo, Sara Cardoso Paes Rose, Nathália Bandeira Freire, Marina Stabile Patrocínio, Natália Pierdoná & Roberto José Bittencourt. (2019) Use of sodium-glucose cotransporter-2 inhibitors and urinary tract infections in type 2 diabetes patients: a systematic review. Revista da Associação Médica Brasileira 65:2, pages 246-252.
Crossref
Crossref
Hongmei Wang, Jiadan Yang, Xi Chen, Feng Qiu & Juan Li. (2019) Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis. Clinical Therapeutics 41:2, pages 322-334.e11.
Crossref
Crossref
Jennifer R Donnan, Catherine A Grandy, Eugene Chibrikov, Carlo A Marra, Kris Aubrey-Bassler, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel Curnew, Hai Nguyen & John-Michael Gamble. (2019) Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open 9:1, pages e022577.
Crossref
Crossref
Takeshi OsonoiMaki GoudaMamiko KuboKenji ArakawaToshio HashimotoMasanori Abe. (2018) Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot Study. Diabetes Technology & Therapeutics 20:10, pages 681-688.
Crossref
Crossref
Xiaoling Cai, Xueying Gao, Wenjia Yang, Yifei Chen, Simin Zhang, Lingli Zhou, Xueyao Han & Linong Ji. (2018) No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis. Journal of Diabetes Investigation 9:4, pages 850-861.
Crossref
Crossref
Shin‐ichi Harashima, Nobuya Inagaki, Kazuoki Kondo, Nobuko Maruyama, Makiko Otsuka, Yutaka Kawaguchi & Yumi Watanabe. (2018) Efficacy and safety of canagliflozin as add‐on therapy to a glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week, open‐label, phase IV study. Diabetes, Obesity and Metabolism 20:7, pages 1770-1775.
Crossref
Crossref
William V Tamborlane, David Polidori, Domenick Argenti & Nicholas A Di Prospero. (2018) Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes. Pediatric Diabetes 19:4, pages 649-655.
Crossref
Crossref
Samuel Seidu, Setor K. Kunutsor, Xavier Cos, Syed Gillani & Kamlesh Khunti. (2018) SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis. Primary Care Diabetes 12:3, pages 265-283.
Crossref
Crossref
Abdullah Kaplan, Emna Abidi, Ahmed El-Yazbi, Ali Eid, George W. Booz & Fouad A. Zouein. (2018) Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects. Heart Failure Reviews 23:3, pages 419-437.
Crossref
Crossref
Nobuya Inagaki, Shin-ichi Harashima, Kohei Kaku, Kazuoki Kondo, Nobuko Maruyama, Makiko Otsuka, Yutaka Kawaguchi & Hiroaki Iijima. (2018) Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 20:4, pages 812-820.
Crossref
Crossref
Edoardo Bertero, Leticia Prates Roma, Pietro Ameri & Christoph Maack. (2018) Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. Cardiovascular Research 114:1, pages 12-18.
Crossref
Crossref
Yuya Seko, Yoshio Sumida, Kazuyo Sasaki, Yoshito Itoh, Hiroaki Iijima, Toshio Hashimoto, Shinichi Ishii & Nobuya Inagaki. (2017) Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials. Journal of Gastroenterology 53:1, pages 140-151.
Crossref
Crossref
Xiaoling Cai, Wenjia Yang, Xueying Gao, Yifei Chen, Lingli Zhou, Simin Zhang, Xueyao Han & Linong Ji. (2018) The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis. Obesity 26:1, pages 70-80.
Crossref
Crossref
Mohsen Mazidi, Peyman Rezaie, Hong‐Kai Gao & Andre Pascal Kengne. (2017) Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients. Journal of the American Heart Association 6:6.
Crossref
Crossref
Emma D. Deeks & André J. Scheen. (2017) Canagliflozin: A Review in Type 2 Diabetes. Drugs 77:14, pages 1577-1592.
Crossref
Crossref
Darin Ruanpeng, Patompong Ungprasert, Jutarat Sangtian & Tasma Harindhanavudhi. (2017) Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis. Diabetes/Metabolism Research and Reviews 33:6, pages e2903.
Crossref
Crossref
E Lioudaki, M Whyte, ES Androulakis, KG Stylianou, EK Daphnis & ES Ganotakis. (2017) Renal Effects of SGLT‐2 Inhibitors and Other Anti‐diabetic Drugs: Clinical Relevance and Potential Risks. Clinical Pharmacology & Therapeutics 102:3, pages 470-480.
Crossref
Crossref
Frederik H. Verbrugge, Pieter Martens & Wilfried Mullens. (2017) SGLT-2 Inhibitors in Heart Failure: Implications for the Kidneys. Current Heart Failure Reports 14:4, pages 331-337.
Crossref
Crossref
Lubin Xu, Yang Li, Jiaxin Lang, Peng Xia, Xinyu Zhao, Li Wang, Yang Yu & Limeng Chen. (2017) Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis. PeerJ 5, pages e3405.
Crossref
Crossref
Takashi Kadowaki, Nobuya Inagaki, Kazuoki Kondo, Kenichi Nishimura, Genki Kaneko, Nobuko Maruyama, Nobuhiro Nakanishi, Hiroaki Iijima, Yumi Watanabe & Maki Gouda. (2017) Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes, Obesity and Metabolism 19:6, pages 874-882.
Crossref
Crossref
Matthew J. Budoff & John P. H. Wilding. (2017) Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. International Journal of Clinical Practice 71:5, pages e12948.
Crossref
Crossref
Eirini Lioudaki, Emmanouil S. Androulakis, Martin Whyte, Konstantinos G. Stylianou, Eugenios K. Daphnis & Emmanouil S. Ganotakis. (2017) The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action. Cardiovascular Drugs and Therapy 31:2, pages 215-225.
Crossref
Crossref
Yoshio Sumida, Yuya Seko & Masashi Yoneda. (2017) Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatology Research 47:4, pages 266-280.
Crossref
Crossref
Pieter Martens, Chantal Mathieu & Frederik H. Verbrugge. (2017) Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond. Current Treatment Options in Cardiovascular Medicine 19:3.
Crossref
Crossref
Lee Ling Lim, Alexander Tong Boon Tan, Kevin Moses, Viraj Rajadhyaksha & Siew Pheng Chan. (2017) Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype. Journal of Diabetes and its Complications 31:2, pages 494-503.
Crossref
Crossref
Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court, J Paul O’Hare, David McGrane, Tim Holt & Norman Waugh. (2017) Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technology Assessment 21:2, pages 1-218.
Crossref
Crossref
S. Nomura. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
349
365
.
Matteo Monami, Ilaria Dicembrini & Edoardo Mannucci. (2016) Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Acta Diabetologica 54:1, pages 19-36.
Crossref
Crossref
Nobuya Inagaki, Shin-ichi Harashima, Nobuko Maruyama, Yutaka Kawaguchi, Maki Goda & Hiroaki Iijima. (2016) Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus. Cardiovascular Diabetology 15:1.
Crossref
Crossref
Wei Xiong, Ming Yue Xiao, Mei Zhang & Fei Chang. (2016) Efficacy and safety of canagliflozin in patients with type 2 diabetes. Medicine 95:48, pages e5473.
Crossref
Crossref
F. Zaccardi, D. R. Webb, Z. Z. Htike, D. Youssef, K. Khunti & M. J. Davies. (2016) Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes, Obesity and Metabolism 18:8, pages 783-794.
Crossref
Crossref
Ele Ferrannini, Michael Mark & Eric Mayoux. (2016) CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care 39:7, pages 1108-1114.
Crossref
Crossref
Helena M. de Wit, Maarten te Groen, Maroeska M. Rovers & Cees J. Tack. (2016)
The placebo response of injectable GLP-1 receptor agonists
vs
. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis
. British Journal of Clinical Pharmacology 82:1, pages 301-314.
Crossref
Crossref
Deepson S Shyangdan, Olalekan A Uthman & Norman Waugh. (2016) SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open 6:2, pages e009417.
Crossref
Crossref
I. Dardi, T. Kouvatsos & S.A. Jabbour. (2016) SGLT2 inhibitors. Biochemical Pharmacology 101, pages 27-39.
Crossref
Crossref
Eva Vivian. (2015) Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus. The Diabetes Educator 41:1_suppl, pages 5S-18S.
Crossref
Crossref
Konstantinos P. Imprialos, Pantelis A. Sarafidis & Asterios I. Karagiannis. (2015) Sodium–glucose cotransporter-2 inhibitors and blood pressure decrease. Journal of Hypertension 33:11, pages 2185-2197.
Crossref
Crossref
Nobuya Inagaki, Maki Goda, Shoko Yokota, Nobuko Maruyama & Hiroaki Iijima. (2015) Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Advances in Therapy 32:11, pages 1085-1103.
Crossref
Crossref
Ting Yang, Min Lu, Lingyue Ma, Ying Zhou & Yimin Cui. (2015) Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis. European Journal of Clinical Pharmacology 71:11, pages 1325-1332.
Crossref
Crossref
Hiroaki Iijima, Takayuki Kifuji, Nobuko Maruyama & Nobuya Inagaki. (2015) Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Advances in Therapy 32:8, pages 768-782.
Crossref
Crossref
Nobuya Inagaki, Kazuoki Kondo, Toru Yoshinari & Hideki Kuki. (2014) Efficacy and safety of canagliflozin alone or as add‐on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52‐week open‐label study. Journal of Diabetes Investigation 6:2, pages 210-218.
Crossref
Crossref
Alisa K. Escaño. 2015. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
521
537
.
André J. Scheen. (2014) Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus. Drugs 75:1, pages 33-59.
Crossref
Crossref